Drugs / ENX-101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05481905 | Sep 2022 → Sep 2024 | focal epilepsy | Engrail Therapeutics INC | Withdrawn | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-06-07 | Engrail Therapeutics INC | Results Engrail Therapeutics Announces Positive Results of ENX-101 Phase 1b Clinical Study and Prepares for Initiation of ENACT Phase 2 Trial in Focal Epilepsy engrail.com ↗
ENX-101, administered orally once daily for ten days, was safe and well tolerated in healthy volunteers. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-06-07 | Engrail Therapeutics INC | Engrail Therapeutics Announces Positive Results of ENX-101 Phase 1b Clinical Study and Prepares for Initiation of ENACT Phase 2 Trial in Focal Epilepsy engrail.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ENX-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05481905 ↗ |